CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...

Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro ...

Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

USDA Animal and Plant Health Inspection Service (APHIS) announced on January 23, 2025, that it is reinstating its legacy ...

There are numerous potential uses for the CRISPR-Cas gene scissors, ranging from antiviral treatments and diagnostics to the ...

A new study links a particular gene to the ancient origins of spoken language, proposing that a protein variant found only in ...

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...

Most mutations that decreased antibiotic susceptibility were related to specific metabolic pathways. A MIC-increase to ...

Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated ...